Arca Biopharma traded at $61.93 this Friday May 15th, decreasing $1.97 or 3.08 percent since the previous trading session. Looking back, over the last four weeks, Arca Biopharma lost 7.66 percent. Over the last 12 months, its price rose by 515.61 percent. Looking ahead, we forecast Arca Biopharma to be priced at 60.69 by the end of this quarter and at 57.10 in one year, according to Trading Economics global macro models projections and analysts expectations.
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.